C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Core Insights - C4 Therapeutics, Inc. has appointed Steve Hoerter to its Board of Directors, emphasizing the company's commitment to enhancing its leadership as it advances its pipeline of targeted protein degraders [1][2] - Hoerter brings over three decades of experience in oncology commercialization, having previously led Deciphera Pharmaceuticals to a successful acquisition by ONO Pharmaceutical for $2.4 billion [2] - The company aims to leverage Hoerter's expertise to guide its transition into a fully integrated biotechnology firm focused on innovative small molecule degraders [2][3] Company Overview - C4 Therapeutics is a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, with a focus on creating new medicines that can transform patient lives [4] - The company utilizes its TORPEDO® platform to design and optimize small-molecule medicines aimed at addressing difficult-to-treat diseases, particularly in oncology [4] - C4T's degrader medicines are designed to exploit the body's natural protein recycling system, potentially overcoming drug resistance and improving patient outcomes [4]